Dr Gerald Chodak reviews a new study reporting extremely favorable long-term outcomes with brachytherapy for prostate cancer, but as usual, there are important caveats.

Drs Cora Sternberg and Stéphane Oudard highlight practice-changing data in prostate cancer, presented at ESMO 2014, including the long-awaited survival results of the COU-AA-302 study.

The FDA is looking more closely into the safety of approved testosterone products. In the meantime, what do we know about treating low T?

Dr Gerald Chodak discusses an FDA panel's recommendation to change labels on testosterone-replacement products in order to discourage their use in 'low T' cases.

Dr. Gerald Chodak discusses a new study that looked for the best way to screen for prostate cancer in African American men and those with a family history of prostate cancer.

Dr. Kathy Miller contrasts standardization of therapy, as demonstrated by pathways, with the trend of individualizing care on the basis of genomics, and asks: Will pathways will lead to extinction?

Dr. Gerald Chodak discusses a new report from the American Cancer Society that provides guidance on long-term care for men who have been diagnosed with prostate cancer.

Dr. Gerald Chodak asks how clinicians can provide a more standardized approach to low-risk prostate cancer.

Dr. Gerald Chodak discusses an FDA panel's recent recommendation against approving high-intensity focused ultrasound (HIFU) for the treatment of prostate cancer.

Are you still doing routine PSA screening? The man who discovered the antigen questions the test's validity.